ELI 007
Alternative Names: ELI-007Latest Information Update: 16 Jun 2024
At a glance
- Originator Elicio Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastrointestinal cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Gastrointestinal cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 03 Nov 2023 Pharmacodynamics data from preclinical studies in Gastrointestinal cancer released by Elicio Therapeutics
- 07 Sep 2023 Elicio Therapeutics plans to submit IND application for Gastrointestinal cancer